Physician profile
Cini Abraham
NPI 1063421576
$6,291.78
in general payments reported to CMS, 2019-2025
23 companies · $913 in 2025
The $913 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $433 · 2021: $599 · 2022: $1,113 · 2023: $1,349 · 2024: $1,468 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,032.65 | 2020-2025 | Caplyta |
| Neuronetics, INC. | $868.16 | 2019-2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $865.62 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $512.81 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $426.16 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $300.35 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $266.60 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $254.41 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $253.05 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $223.80 | 2022-2023 | Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $218.14 | 2019-2024 | Trintellix |
| Allergan, INC. | $204.60 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $197.39 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $182.02 | 2020-2021 | |
| Corium, LLC | $110.34 | 2022-2024 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $94.21 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Neurocrine Biosciences, INC. | $67.14 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $52.85 | 2024-2025 | Fanapt |
| Almatica Pharma LLC | $52.71 | 2024 | Loreev Xr |
| Alkermes, INC. | $34.40 | 2024-2025 | Lybalvi, Aristada |
| Brainsway USA INC | $29.25 | 2023 | |
| Adlon Therapeutics L.P. | $28.26 | 2020-2021 | |
| Tempus Ai, INC | $16.86 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cini Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.